The Experts below are selected from a list of 6051 Experts worldwide ranked by ideXlab platform
Chaim M Bell - One of the best experts on this subject based on the ideXlab platform.
-
gastrointestinal adverse events with sodium Polystyrene Sulfonate kayexalate use a systematic review
The American Journal of Medicine, 2013Co-Authors: Ziv Harel, Shai Harel, Prakesh S Shah, Ron Wald, Jeffrey Perl, Chaim M BellAbstract:Abstract Background Sodium Polystyrene Sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events. Although the addition of sorbitol to sodium Polystyrene Sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium Polystyrene Sulfonate itself may be toxic. Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Methods MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Causality criteria of the World Health Organization causality assessment system were applied to each report. Results Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified. The colon was the most common site of injury (n=44; 76%), and transmural necrosis (n=36; 62%) was the most common histopathologic lesion reported. Mortality was reported in 33% of these cases due to gastrointestinal injury. Conclusions Sodium Polystyrene Sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury. Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia.
-
Gastrointestinal adverse events with sodium Polystyrene Sulfonate (Kayexalate) use: a systematic review.
The American journal of medicine, 2013Co-Authors: Ziv Harel, Shai Harel, Prakesh S Shah, Ron Wald, Jeffrey Perl, Chaim M BellAbstract:Sodium Polystyrene Sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events. Although the addition of sorbitol to sodium Polystyrene Sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium Polystyrene Sulfonate itself may be toxic. Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Causality criteria of the World Health Organization causality assessment system were applied to each report. Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified. The colon was the most common site of injury (n=44; 76%), and transmural necrosis (n=36; 62%) was the most common histopathologic lesion reported. Mortality was reported in 33% of these cases due to gastrointestinal injury. Sodium Polystyrene Sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury. Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia. Copyright © 2013 Elsevier Inc. All rights reserved.
Ziv Harel - One of the best experts on this subject based on the ideXlab platform.
-
Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age
JAMA internal medicine, 2019Co-Authors: J. Ariana Noel, Ziv Harel, Sarah E. Bota, William Petrcich, Amit X. Garg, Juan Jesus Carrero, Navdeep Tangri, Edward G. Clark, Paul Komenda, Manish M. SoodAbstract:Importance Sodium Polystyrene Sulfonate is commonly prescribed for the treatment of hyperkalemia. Case reports of intestinal injury after administration of sodium Polystyrene Sulfonate with sorbitol resulted in a US Food and Drug Administration warning and discontinuation of combined 70% sorbitol–sodium Polystyrene Sulfonate formulations. There are ongoing concerns about the gastrointestinal (GI) safety of sodium Polystyrene Sulfonate use. Objective To assess the risk of hospitalization for adverse GI events associated with sodium Polystyrene Sulfonate use in patients of advanced age. Design, Setting, and Participants Population-based, retrospective matched cohort study of eligible adults of advanced age (≥66 years) dispensed sodium Polystyrene Sulfonate from April 1, 2003, to September 30, 2015, in Ontario, Canada, with maximum follow-up to March 31, 2016. Initial data analysis was conducted from August 1, 2018, to October 3, 2018; revision analysis was conducted from February 25, 2019, to April 2, 2019. Cox proportional hazards regression models were used to examine the association of sodium Polystyrene Sulfonate use with a composite of GI adverse events compared with nonuse that was matched via a high-dimensional propensity score. Additional analyses were limited to a subpopulation with baseline laboratory values of estimated glomerular filtration rate and serum potassium level. Exposure Dispensed sodium Polystyrene Sulfonate in an outpatient setting. Main Outcomes and Measures The primary outcome was a composite of adverse GI events (hospitalization or emergency department visit with intestinal ischemia/thrombosis, GI ulceration/perforation, or resection/ostomy) within 30 days of initial sodium Polystyrene Sulfonate prescription. Results From a total of 1 853 866 eligible adults, 27 704 individuals were dispensed sodium Polystyrene Sulfonate (mean [SD] age, 78.5 [7.7] years; 54.7% male), and 20 020 sodium Polystyrene Sulfonate users were matched to 20 020 nonusers. Sodium Polystyrene Sulfonate use compared with nonuse was associated with a higher risk of an adverse GI event over the following 30 days (37 events [0.2%]; incidence rate, 22.97 per 1000 person-years vs 18 events [0.1%]; incidence rate, 11.01 per 1000 person-years) (hazard ratio, 1.94; 95% CI, 1.10-3.41). Results were consistent in additional analyses, including the subpopulation with baseline laboratory values (hazard ratio, 2.91; 95% CI, 1.38-6.12), and intestinal ischemia/thrombosis was the most common type of GI injury. Conclusions and Relevance The use of sodium Polystyrene Sulfonate is associated with a higher risk of hospitalization for serious adverse GI events. These findings require confirmation and suggest caution with the ongoing use of sodium Polystyrene Sulfonate.
-
gastrointestinal adverse events with sodium Polystyrene Sulfonate kayexalate use a systematic review
The American Journal of Medicine, 2013Co-Authors: Ziv Harel, Shai Harel, Prakesh S Shah, Ron Wald, Jeffrey Perl, Chaim M BellAbstract:Abstract Background Sodium Polystyrene Sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events. Although the addition of sorbitol to sodium Polystyrene Sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium Polystyrene Sulfonate itself may be toxic. Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Methods MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Causality criteria of the World Health Organization causality assessment system were applied to each report. Results Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified. The colon was the most common site of injury (n=44; 76%), and transmural necrosis (n=36; 62%) was the most common histopathologic lesion reported. Mortality was reported in 33% of these cases due to gastrointestinal injury. Conclusions Sodium Polystyrene Sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury. Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia.
-
Gastrointestinal adverse events with sodium Polystyrene Sulfonate (Kayexalate) use: a systematic review.
The American journal of medicine, 2013Co-Authors: Ziv Harel, Shai Harel, Prakesh S Shah, Ron Wald, Jeffrey Perl, Chaim M BellAbstract:Sodium Polystyrene Sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events. Although the addition of sorbitol to sodium Polystyrene Sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium Polystyrene Sulfonate itself may be toxic. Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Causality criteria of the World Health Organization causality assessment system were applied to each report. Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified. The colon was the most common site of injury (n=44; 76%), and transmural necrosis (n=36; 62%) was the most common histopathologic lesion reported. Mortality was reported in 33% of these cases due to gastrointestinal injury. Sodium Polystyrene Sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury. Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia. Copyright © 2013 Elsevier Inc. All rights reserved.
Andrew B Bocarsly - One of the best experts on this subject based on the ideXlab platform.
-
ion exchange resin Polystyrene Sulfonate composite membranes for pem fuel cells
Journal of Membrane Science, 2004Co-Authors: Shengli Chen, Lakshmi Krishnan, S Srinivasan, Jay B Benziger, Andrew B BocarslyAbstract:Abstract A new composite proton exchange membrane was made by casting a Polystyrene Sulfonate (PSS) solution with suspended micron sized particles of a crosslinked PSS ion exchange resin. The chemical compatibility of the resin and the PSS allow stable composites with up to 50 wt.% resin. The resin/PSS composite membranes have greater ion exchange capacity than PSS membranes, but the ion conductivity is similar to that of PSS. Swelling of the composite membranes as a function of water uptake is lower than that of PSS. The composite membranes are mechanically more robust and display greater chemical stability in a fuel cell than the PSS membranes. The polarization curves show long-term degradation of the membranes; the cell potential decreased by 60% in 55 h for a PSS membrane, and in 340 h for a composite membrane. The reduced rate of degradation of the composite membranes suggests that with further refinement they may have potential as an inexpensive alternative for PEM fuel cells.
Alan J Heeger - One of the best experts on this subject based on the ideXlab platform.
-
polymer light emitting diodes with polyethylene dioxythiophene Polystyrene Sulfonate as the transparent anode
Synthetic Metals, 1997Co-Authors: G Yu, C Zhang, Reghu Menon, Alan J HeegerAbstract:Abstract Polyethylene dioxythiophene–Polystyrene Sulfonate (PEDT–PSS) thin films spin-cast from aqueous dispersion have been used as semi-transparent anodes for polymer light-emitting diodes (LEDs). An external quantum efficiency of 2.0% was achieved with poly(2-methoxy,5-(2′-ethyl-hexyloxy)-1,4-phenylene vinylene) (MEH–PPV), as the semiconducting luminescent polymer. LEDs fabricated with the PEDT–PSS anode exhibit an enhanced stress life in excess of 500 h at 70 mA/cm2 under constant-current conditions (initial brightness 600 cd/m2, reduced to 450 cd/m2 after 500 h).
-
Polymer light-emitting diodes with polyethylene dioxythiophene–Polystyrene Sulfonate as the transparent anode
Synthetic Metals, 1997Co-Authors: Yong Cao, C Zhang, Reghu Menon, Alan J HeegerAbstract:Abstract Polyethylene dioxythiophene–Polystyrene Sulfonate (PEDT–PSS) thin films spin-cast from aqueous dispersion have been used as semi-transparent anodes for polymer light-emitting diodes (LEDs). An external quantum efficiency of 2.0% was achieved with poly(2-methoxy,5-(2′-ethyl-hexyloxy)-1,4-phenylene vinylene) (MEH–PPV), as the semiconducting luminescent polymer. LEDs fabricated with the PEDT–PSS anode exhibit an enhanced stress life in excess of 500 h at 70 mA/cm2 under constant-current conditions (initial brightness 600 cd/m2, reduced to 450 cd/m2 after 500 h).
Prakesh S Shah - One of the best experts on this subject based on the ideXlab platform.
-
gastrointestinal adverse events with sodium Polystyrene Sulfonate kayexalate use a systematic review
The American Journal of Medicine, 2013Co-Authors: Ziv Harel, Shai Harel, Prakesh S Shah, Ron Wald, Jeffrey Perl, Chaim M BellAbstract:Abstract Background Sodium Polystyrene Sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events. Although the addition of sorbitol to sodium Polystyrene Sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium Polystyrene Sulfonate itself may be toxic. Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Methods MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Causality criteria of the World Health Organization causality assessment system were applied to each report. Results Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified. The colon was the most common site of injury (n=44; 76%), and transmural necrosis (n=36; 62%) was the most common histopathologic lesion reported. Mortality was reported in 33% of these cases due to gastrointestinal injury. Conclusions Sodium Polystyrene Sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury. Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia.
-
Gastrointestinal adverse events with sodium Polystyrene Sulfonate (Kayexalate) use: a systematic review.
The American journal of medicine, 2013Co-Authors: Ziv Harel, Shai Harel, Prakesh S Shah, Ron Wald, Jeffrey Perl, Chaim M BellAbstract:Sodium Polystyrene Sulfonate (Kayexalate; Sanofi-Aventis, Paris, France) is a cation-exchange resin routinely used in the management of hyperkalemia. However, its use has been associated with colonic necrosis and other fatal gastrointestinal adverse events. Although the addition of sorbitol to sodium Polystyrene Sulfonate preparations was previously believed to be the cause of gastrointestinal injury, recent reports have suggested that sodium Polystyrene Sulfonate itself may be toxic. Our objective was to systematically review case reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (1993 to July 27, 2011), bibliographies of identified articles, and websites of relevant drug agencies and professional associations in the United States and Canada were reviewed to identify eligible reports of adverse gastrointestinal events associated with sodium Polystyrene Sulfonate use. Causality criteria of the World Health Organization causality assessment system were applied to each report. Thirty reports describing 58 cases (41 preparations containing sorbitol and 17 preparations without sorbitol) of adverse events were identified. The colon was the most common site of injury (n=44; 76%), and transmural necrosis (n=36; 62%) was the most common histopathologic lesion reported. Mortality was reported in 33% of these cases due to gastrointestinal injury. Sodium Polystyrene Sulfonate use, both with and without sorbitol, may be associated with fatal gastrointestinal injury. Physicians must be cognizant of the risk of these adverse events when prescribing this therapy for the management of hyperkalemia. Copyright © 2013 Elsevier Inc. All rights reserved.